Form 4: Director Michel Lagarde Receives Vertex Stock Options

Vertex Pharmaceuticals Director Michel Lagarde was granted 2,866 fully vested stock options with an exercise price of $424.45.

Summary

• Director Michel Lagarde acquired 2,866 stock options in Vertex Pharmaceuticals (VRTX).
• The options have an exercise price of $424.45 per share.
• The options are fully vested upon grant.
• The expiration date for these options is April 30, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative disclosure regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard compensatory equity grant for a director.

Risks

• None identified; this is a routine disclosure of director compensation.

Future Outlook

Not applicable as this is a retrospective disclosure of an equity grant.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure long-term alignment between leadership and shareholders.

Comparison to Industry Standards

• The grant of fully vested options is consistent with standard director compensation packages for large-cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• None

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Form 4, Insider Trading, Director Compensation, Stock Options